MR-Guided Cryoablation of Prostate Bed Recurrences
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01727284 |
Recruitment Status :
Recruiting
First Posted : November 15, 2012
Last Update Posted : January 10, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Prostate Tumors | Procedure: MR-guided cryoablation | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Technical Success, Safety, and Short and Long-term Efficacy for MR-Guided Cryoablation of Prostate Bed Recurrences |
Actual Study Start Date : | December 12, 2012 |
Estimated Primary Completion Date : | July 2023 |
Estimated Study Completion Date : | July 2023 |

Arm | Intervention/treatment |
---|---|
MR-guided cryoablation (freezing of tissue and/or tumors) |
Procedure: MR-guided cryoablation |
- Evaluation of target lesion at 3-6, 12, 24, and 36 month imaging follow-up [ Time Frame: 3 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 30 Years to 100 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with "biopsy proven" soft tissue tumor recurrences of prostate fossa
- Surgery is not a desirable alternative therapy at the time of enrollment
- Radiation therapy has failed or not indicated or can be safely postponed
- Tumor size is < 5 cm at its largest diameter
- Tumor does not encompass the rectal wall or external urethral sphincter
- Performance status is ECOG 2 or better in adults
- Patient is able to undergo MRI
Exclusion Criteria:
- Patients with pacemaker or defibrillator

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01727284
Contact: Jennifer Murphy | 507-538-0540 | Murphy.Jennifer@mayo.edu | |
Contact: Desirae Howe-Clayton | 507-255-0111 | Howe.Desirae@mayo.edu |
United States, Minnesota | |
Mayo Clinic in Rochester | Recruiting |
Rochester, Minnesota, United States, 55905 | |
Contact: Jennifer Murphy 507-538-0540 Murphy.Jennifer@mayo.edu | |
Principal Investigator: David A Woodrum, M.D., Ph.D. |
Principal Investigator: | David Woodrum, MD, PhD | Mayo Clinic |
Responsible Party: | David A. Woodrum, Assistant Professor of Radiology, Mayo Clinic |
ClinicalTrials.gov Identifier: | NCT01727284 |
Other Study ID Numbers: |
12-002245 |
First Posted: | November 15, 2012 Key Record Dates |
Last Update Posted: | January 10, 2023 |
Last Verified: | January 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Recurrence Disease Attributes Pathologic Processes |